Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
COVID-19-mortaliteit bij kankerpatiënten - impact van behandeling
aug 2020 | Immuuntherapie